Drug
Xiidra®
Xiidra® is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_4
2
67%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 42 (66.7%)
Trials by Status
active_not_recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_4
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07025811
completedphase_1
Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
NCT07040826
completedphase_4
The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers
NCT04297618
Clinical Trials (3)
Showing 3 of 3 trials
NCT07025811Phase 4
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07040826Phase 1
Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
NCT04297618Phase 4
The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3